Venera Miller
Psychiatry · Prince Frederick, MDNPI 1053349902
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.6% of the total across 335 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 19.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,555, 2.7 times the $569 reported in 2019. Among psychiatry clinicians in MD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 335 payments — averaging $17.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Vanda Pharmaceuticals Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$859
- Lundbeck LLC$839
- Otsuka America Pharmaceutical, Inc.$421
- Indivior Inc.$399
- plus $1K from 14 others
What the payments were for
- Food & beverage$5,78399%
- Education$801%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 83 | $1,151 |
| Vanda Pharmaceuticals Inc. | 55 | $1,040 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 37 | $859 |
| Lundbeck LLC | 52 | $839 |
| Otsuka America Pharmaceutical, Inc. | 24 | $421 |
| Indivior Inc. | 17 | $399 |
| Axsome Therapeutics, Inc. | 11 | $211 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $196 |
| Alkermes, Inc. | 10 | $191 |
| Shire North American Group Inc | 10 | $152 |
| Supernus Pharmaceuticals, Inc. | 5 | $103 |
| Sunovion Pharmaceuticals Inc. | 4 | $58 |
| Braeburn Inc. | 3 | $54 |
| Neurocrine Biosciences, Inc. | 3 | $40 |
| Corium, LLC | 3 | $33 |
| Orexo US, Inc. | 2 | $32 |
| Neuronetics, Inc. | 2 | $26 |
| Johnson & Johnson | 1 | $20 |
| Avanir Pharmaceuticals, Inc. | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,863 in reported general payments places this provider in the 90th percentile of 851 psychiatry providers in Maryland.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lurasidone Hcl | 19 | $4,513 |
| Fluoxetine Hcl | 23 | $1,661 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 13 | $1,592 |
| Lamotrigine ErLamotrigine | 12 | $1,488 |
| Olanzapine | 16 | $679 |
| Lamotrigine | 28 | $646 |
| Hydroxyzine Hcl | 31 | $632 |
| Trazodone Hcl | 48 | $599 |
| Duloxetine Hcl | 30 | $565 |
| Clonazepam | 80 | $555 |
| Eszopiclone | 22 | $457 |
| Oxcarbazepine | 12 | $414 |
| Escitalopram Oxalate | 40 | $408 |
| Quetiapine Fumarate | 38 | $349 |
| Prazosin Hcl | 15 | $321 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Prince Frederick
- Osama SalehPrince Frederick$15K
- John VaethBaltimore$2.1M
- Scott AaronsonBaltimore$334K
- Jamal FawazHagerstown$321K
- Thomas LaughrenRockville$283K
- Adam RothAnnapolis$210K
- Robert LehmanBaltimore$140K
- Karen AndersonBaltimore$117K
- Orlando DavisBaltimore$104K
- Paul LeberPotomac$85K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.